利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

13 条记录 (耗时 0.043 秒)

    Human antigen binding proteins that bind β-klotho, FGF receptors and complexes thereof
    6.
    发明授权
    Human antigen binding proteins that bind β-klotho, FGF receptors and complexes thereof 有权
    结合β-klotho，FGF受体及其复合物的人抗原结合蛋白

    公开(公告)号：US09493577B2

    公开(公告)日：2016-11-15

    申请号：US15012939

    申请日：2016-02-02

    申请人： Amgen Inc.

    发明人： Shaw-Fen Sylvia Hu ,  Ian Nevin Foltz ,  Chadwick Terence King ,  Yang Li ,  Taruna Arora

    IPC分类号： A61K39/395 ,  C07K16/40 ,  C07K14/71 ,  C07K16/18 ,  C07K16/28 ,  A61K39/00

    CPC分类号： C07K16/2863 ,  A61K2039/505 ,  C07K14/71 ,  C07K16/18 ,  C07K16/28 ,  C07K16/40 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/32 ,  C07K2317/34 ,  C07K2317/53 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/626 ,  C07K2317/75 ,  C07K2317/92 ,  C07K2319/30

    摘要： The present invention provides compositions and methods relating to or derived from antigen binding proteins activate FGF21-mediated signaling. In embodiments, the antigen binding proteins specifically bind to (i) β-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising β-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4. In some embodiments the antigen binding proteins induce FGF21-like signaling. In some embodiments, an antigen binding protein is a fully human, humanized, or chimeric antibodies, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to (i) β-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising β-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4. Other embodiments provide nucleic acids encoding such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, cells comprising such polynucleotides, methods of making such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, and methods of using such antigen binding proteins, fragments and derivatives thereof, and polypeptides, including methods of treating or diagnosing subjects suffering from type 2 diabetes, obesity, NASH, metabolic syndrome and related disorders or conditions.

    摘要翻译： 本发明提供与抗原结合蛋白有关或衍生自抗原结合蛋白的组合物和方法激活FGF21介导的信号传导。 在实施方案中，抗原结合蛋白特异性结合（i）β-Klotho; （ii）FGFR1c，FGFR2c，FGFR3c或FGFR4; 或（iii）包含β-Klotho和FGFR1c，FGFR2c，FGFR3c和FGFR4之一的复合物。 在一些实施方案中，抗原结合蛋白诱导FGF21样信号传导。 在一些实施方案中，抗原结合蛋白是完全人，人源化或嵌合抗体，所述抗体的结合片段和衍生物，以及特异性结合（i）β-Klotho的多肽; （ii）FGFR1c，FGFR2c，FGFR3c或FGFR4; 或（iii）包含β-Klotho和FGFR1c，FGFR2c，FGFR3c和FGFR4之一的复合物。 其它实施方案提供了编码这种抗原结合蛋白的核酸及其片段和衍生物，以及多肽，包含这种多核苷酸的细胞，制备此类抗原结合蛋白的方法及其片段和衍生物以及多肽，以及使用这些抗原结合蛋白的方法 ，其片段及其衍生物和多肽，包括治疗或诊断患有2型糖尿病，肥胖症，NASH，代谢综合征和相关疾病或病症的受试者的方法。

    CHIMERIC POLYPEPTIDES AND USES THEREOF
    9.
    发明申请
    CHIMERIC POLYPEPTIDES AND USES THEREOF 审中-公开
    CHIMERIC POLYPEPTIDES及其用途

    公开(公告)号：US20130143796A1

    公开(公告)日：2013-06-06

    申请号：US13680986

    申请日：2012-11-19

    申请人： AMGEN INC.

    发明人： Yang Li ,  Xinle Wu ,  Zhulun Wang

    IPC分类号： C07K14/50

    CPC分类号： C07K14/50 ,  C07K16/22 ,  C07K2319/00

    摘要： The disclosure provides nucleic acid molecules encoding chimeric polypeptides, chimeric polypeptides, pharmaceutical compositions comprising chimeric polypeptides, and methods for treating metabolic disorders such as diabetes and obesity using such nucleic acids, polypeptides, or pharmaceutical compositions.

    摘要翻译： 本公开内容提供了编码嵌合多肽的核酸分子，嵌合多肽，包含嵌合多肽的药物组合物，以及使用这种核酸，多肽或药物组合物治疗代谢性疾病如糖尿病和肥胖症的方法。

    Human antigen binding proteins that bind β-Klotho, FGF receptors and complexes thereof
    10.
    发明授权
    Human antigen binding proteins that bind β-Klotho, FGF receptors and complexes thereof 有权

    公开(公告)号：US10570205B2

    公开(公告)日：2020-02-25

    申请号：US15280662

    申请日：2016-09-29

    申请人： AMGEN INC.

    发明人： Shaw-Fen Sylvia Hu ,  Ian Nevin Foltz ,  Chadwick Terence King ,  Yang Li ,  Taruna Arora

    IPC分类号： A61K39/00 ,  C07K16/28 ,  C07K16/40 ,  C07K14/71 ,  C07K16/18

    摘要： The present invention provides compositions and methods relating to or derived from antigen binding proteins activate FGF21-mediated signaling. In embodiments, the antigen binding proteins specifically bind to (i) β-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising β-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4. In some embodiments the antigen binding proteins induce FGF21-like signaling. In some embodiments, an antigen binding protein is a fully human, humanized, or chimeric antibodies, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to (i) β-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising β-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4. Other embodiments provide nucleic acids encoding such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, cells comprising such polynucleotides, methods of making such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, and methods of using such antigen binding proteins, fragments and derivatives thereof, and polypeptides, including methods of treating or diagnosing subjects suffering from type 2 diabetes, obesity, NASH, metabolic syndrome and related disorders or conditions.